热门资讯> 正文

Neurogene GAAP每股收益为-1.19美元

2024-11-19 14:55

Neurogene press release (NASDAQ:NGNE): Q3 GAAP EPS of -$1.19 in-line.
Cash, cash equivalents and investments as of September 30, 2024 were $139.0 million.
The company continues to expect current cash, cash equivalents and marketable securities, together with an estimated $189.5 million in net proceeds from the private placement, to fund operations into the second half of 2027.

More on Neoleukin Therapeutics

Neurogene: Interesting CNS Disease Company, Data Coming Soon
Neurogene stock plunges 36% on NGN-401 study update
Neurogene plummets 35% on gene therapy trial data for Rett syndrome
Historical earnings data for Neoleukin Therapeutics
Financial information for Neoleukin Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。